MLLCF (Molecular Partners AG) SpecialCharges

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MLLCF Molecular Partners AG MLLCF
25 GF Score
Price $3.80
GF Value $0.51
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Molecular Partners AG SpecialCharges?

Special Charges only applies to banks.

MLLCF
25GF Score
Molecular Partners AG MLLCF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Molecular Partners AG (MLLCF) Overvalued in 2026?

Based on GuruFocus' analysis, Molecular Partners AG stock appears to be overvalued. The current stock price of $3.80 is trading 645.1% above its estimated GF Value™ of $0.51. GuruFocus considers Molecular Partners AG to be Significantly Overvalued.

Key valuation signals for MLLCF:

  • SpecialCharges:
  • GF Value™: $0.51 vs. price of $3.80 (645.1% above fair value)
  • GF Score™: 25/100 with 3 warning signs

No single metric tells the full story. See the MLLCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Molecular Partners AG Business Description

Address Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
25GF Score

Get the complete analysis for MLLCF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.80
Price
$0.51
GF Value